Costs for Breast Cancer Care in the Military Health System: An Analysis by Benefit Type and Care Source

Military Medicine

Volumn 183, Issue 11-12, 2018, Pages E500-E508

  Eaglehouse, Yvonne L ^a,b   Manjelievskaia, Janna ^a   Shao, Stephanie ^a   Brown, Derek ^a   Hofmann, Keith ^c   Richard, Patrick ^b   Shriver, Craig D ^a,b   Zhu, Kangmin ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b Uniformed Services University of the Health Sciences   (United States)

^c Kennell and Associates Inc   (United States)

Author keywords

breast cancer; direct care; healthcare expenditures; insurance type; purchased care

Indexed keywords

ADULT; BREAST TUMOR; CHI SQUARE DISTRIBUTION; COMPLICATION; COST BENEFIT ANALYSIS; DRUG THERAPY; ECONOMICS; FEMALE; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; MASTECTOMY; MIDDLE AGED; RADIOTHERAPY; RECONSTRUCTIVE SURGERY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DRUG THERAPY; FEMALE; HEALTH CARE COSTS; HUMANS; MASTECTOMY; MIDDLE AGED; RADIOTHERAPY; RECONSTRUCTIVE SURGICAL PROCEDURES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 85057521044     PISSN: 00264075     EISSN: 1930613X     Source Type: Journal    
DOI: 10.1093/milmed/usy052     Document Type: Article

References (43)

1. National Cancer Institute. Office of Cancer Survivorship: Statistics. 2016. cancercontrol.cancer.gov/ocs/statistics; accessed June 20, 2017.
2. Yabroff KR, Lund J, Kepka D, et al: Economic burden of cancer in the United States: Estimates, projections, and future research. Cancer Epidemiol, Biomarkers Prev 2011; 20(10): 2006-14. doi:10.1158/1055-9965.epi-11-0650.
3. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011; 103 (2): 117-28.
4. Brown ML, Riley GF, Schussler N, et al: Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002; 40(8 Suppl): IV-17.
5. Etzioni R, Riley GF, Ramsey SD, et al: Measuring costs: Administrative claims data, clinical trials, and beyond. Med Care 2002; 40(6 Suppl): III63-72.
6. Kongstvedt PR: Essentials of Managed Health Care-Sixth Edition, Ed 6, Burlington, MA, Jones & Bartlett Learning, 2013.
7. Blumen H, Fitch K, Polkus V: Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am Health Drug Benefits 2016; 9(1): 23-32.
8. Smith BD, Jiang J, Shih YC, et al: Cost and complications of local therapies for early-stage breast cancer. J Natl Cancer Inst 2017; 109: 1.
9. Xu X, Herrin J, Soulos PR, et al: The role of patient factors, cancer characteristics, and treatment patterns in the cost of care for medicare beneficiaries with breast cancer. Health Serv Res 2016; 51(1): 167-86.
10. Shirvani SM, Jiang J, Likhacheva A, et al: Trends in local therapy utilization and cost for early-stage breast cancer in older women: Implications for payment and policy reform. Int J Radiat Oncol Biol Phys 2016; 95(2): 605-16.
11. Onega T, Tosteson AN, Weiss J, et al: Costs of diagnostic and preoper-ative workup with and without breast MRI in older women with a breast cancer diagnosis. BMC Health Serv Res 2016; 16: 76.
12. Feinstein AJ, Long J, Soulos PR, et al: Older women with localized breast cancer: Costs and survival rates increased across two time periods. Health Aff (Millwood) 2015; 34(4): 592-600.
13. Boero IJ, Paravati AJ, Triplett DP, et al: The impact of radiotherapy costs on clinical outcomes in breast cancer. Radiother Oncol 2015; 117(2): 393-9.
14. Hassett MJ, Neville BA, Weeks JC: The relationship between quality, spending and outcomes among women with breast cancer. J Natl Cancer Inst 2014; 106: 10.
15. Fu AZ, Jhaveri M: Healthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United States. J Med Econ 2012; 15(4): 688-94. doi:10.3111/13696998.2012.673524.
16. Barron JJ, Quimbo R, Nikam PT, et al: Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat 2008; 109(2): 367-77. doi:10.1007/s10549-007-9650-4.
17. Defense Health Agency. TRICARE. 2016. www.tricare.mil.
18. Jansen DJ. Military Medical Care: Questions and Answers. Congressional Research Service, editor. 2014. http://fas.org/sgp/crs/misc/RL33537.pdf.
19. National Health Statistics Group. National health expenditures by type of service and source of funds: Calendar years 1960 to 2015. In: U.S. Centers for Medicare & Medicaid Services Office of the Actuary, editor. www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/nationalhealthexpenddata/2016.
20. Military Health System and Defense Health Agency. Rates and Reimbursement. 2017. health.mil/military-health-topics/business-support/rates-and-reimbursement; accessed April 5, 2017.
21. Enewold L, McGlynn KA, Zahm SH, et al: Surveillance mammography among female Department of Defense beneficiaries: A study by race and ethnicity. Cancer 2013; 119(19): 3531-8. doi:10.1002/cncr.28242.
22. Enewold LR, McGlynn KA, Zahm SH, et al: Breast reconstruction after mastectomy among Department of Defense beneficiaries by race. Cancer 2014; 120(19): 3033-9. doi:10.1002/cncr.28806.
23. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40(5): 373-83.
24. Warren JL, Brown ML, Fay MP, et al: Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol 2002; 20(1): 307-16.
25. Virnig BA, Warren JL, Cooper GS, et al: Studying radiation therapy using SEER-Medicare-linked data. Med Care 2002; 40(8 Suppl): Iv-49-54. doi:10.1097/01.mlr.0000020940.90270.4d.
26. Warren JL, Yabroff KR, Meekins A, et al: Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008; 100(12): 888-97.
27. United States Department of Labor. Consumer Price Index. In: Archived Consumer Price Index Detailed Report. www.bls.gov/cpi. 2017. www.bls.gov/cpi; accessed April 3, 2017.
28. Beaumont JL, Lix LM, Yost KJ, et al: Application of robust statistical methods for sensitivity analysis of health-related quality of life outcomes. Qual Life Res 2006; 15(3): 349-56. doi:10.1007/s11136-005-2293-1.
29. Wilcox RR, Keselman HJ, Muska J, et al: Repeated measures ANOVA: Some new results on comparing trimmed means and means. Br J Math Stat Psychol 2000; 53(Pt 1): 69-82.
30. Vardeman S, Meeden G: Admissible estimators of the population total using trimming and Winsorization. Stat Probab Lett 1983; 1(6): 317-21. doi:http://dx.doi.org/10.1016/0167-7152(83)90052-4.
31. Gentleman WM. Basic Procedures for Large, Sparse, or Weighted Linear Least Squares Problems. University of Waterloo, Canada; 1972.
32. Gentleman WM.: Least squares computations by givens transformations without square roots. IMA J Appl Math 1973; 12(3): 329-36. doi:10. 1093/imamat/12.3.329.
33. Defense Health Agency, Defense Health Cost Assessment and Program Evaluation, Office of the Assistant Secretary of Defense (Health Affairs). Evaulation of the TRICARE Program: Fiscal Year 2014 Report to Congress. February 25, 2014. https://health.mil/Reference-Center/Reports.
34. Woolhandler S, Himmelstein DU: Costs of care and administration at for-profit and other hospitals in the United States. N Engl J Med 1997; 336(11): 769-74. doi:10.1056/nejm199703133361106.
35. Sen S, Soulos PR, Herrin J, et al: For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery. Surgery 2014; 155(5): 776-88. doi:10.1016/j.surg.2013.12.009.
36. Epstein AJ, Johnson SJ: Physician response to financial incentives when choosing drugs to treat breast cancer. Int J Health Care Finance Econ 2012; 12(4): 285-302. doi:10.1007/s10754-012-9117-y.
37. Fuchs VR.: The basic forces influencing costs of medical care. In: Essays in the Economics of Health and Medical Care, pp 39-50. Edited by Fuchs VR. Cambridge, MA, National Bureau of Economic Research, 1972.
38. Sail KR, Franzini L, Lairson DR, et al: Clinical and economic outcomes associated with adjuvant chemotherapy in elderly patients with early stage operable breast cancer. Value in health: The journal of the International Society for Pharmacoeconomics and Outcomes. Research 2012; 15(1): 72-80. doi:10.1016/j.jval.2011.10.004.
39. Mittmann N, Porter JM, Rangrej J, et al: Health system costs for stage-specific breast cancer: A population-based approach. Curr Oncol 2014; 21(6): 281-93. doi:10.3747/co.21.2143.
40. Broekx S, Den Hond E, Torfs R, et al: The costs of breast cancer prior to and following diagnosis. European J Health Econ 2011; 12(4): 311-7. doi:10.1007/s10198-010-0237-3.
41. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer [database on the Internet]2017. Accessed
42. Jacobson M, O'Malley AJ, Earle CC, et al: Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood) 2006; 25(2): 437-43.
43. Hornbrook MC, Malin J, Weeks JC, et al: Did changes in drug reimbursement after the medicare modernization act affect chemotherapy prescribing? J Clin Oncol 2014; 32(36): 4042-9. doi:10.1200/jco.2013. 52.6780.